Ilene Wiggins, RN

CRS:

JHU

Role:

Clinical

Position:

Senior Research Nurse Program Manager for the Johns Hopkins CTU

Email:

iwiggin1@jhmi.edu

As CTU/CRS Coordinator/Research Manager, Ms. Wiggins is responsible for the day-to-day operations of the CTU with respect to domestic (U.S.) research activities. Ms. Wiggins has been a nurse coordinator for the Johns Hopkins AIDS Clinical Trials Unit (ACTU) for more than 20 years, and has been Research Manager/Coordinator for this Unit since 2002. In this role, she works closely with the PI’s, CRS Leaders and investigators to plan and execute the CTU’s scientific activities.

  • Chair, Site Management and Clinical Care Committee (Dec 2016)
  • SMCCC Representative, Protocol Development and implementation Subcommittee of the SMCCC (Dec 2015)
  • SMCCC Representative, Site Operations Subcommittee of the SMCCC (Dec 2016)
  • SMCCC Representative, Training and Education Working Group of the SOS (Dec 2015)
  • Member, Study Coordinators Working Group of the SOS (Jun 2011)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More